CO5080735A1 - Agonistas de prostaglandinas - Google Patents
Agonistas de prostaglandinasInfo
- Publication number
- CO5080735A1 CO5080735A1 CO98035644A CO98035644A CO5080735A1 CO 5080735 A1 CO5080735 A1 CO 5080735A1 CO 98035644 A CO98035644 A CO 98035644A CO 98035644 A CO98035644 A CO 98035644A CO 5080735 A1 CO5080735 A1 CO 5080735A1
- Authority
- CO
- Colombia
- Prior art keywords
- independently
- optionally
- rings
- elements
- sulfur
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- 150000003180 prostaglandins Chemical class 0.000 title 1
- 229910052757 nitrogen Chemical group 0.000 abstract 16
- 229920006395 saturated elastomer Polymers 0.000 abstract 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 12
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 7
- 229910052760 oxygen Inorganic materials 0.000 abstract 7
- 239000001301 oxygen Substances 0.000 abstract 7
- 229910052717 sulfur Inorganic materials 0.000 abstract 7
- 239000011593 sulfur Chemical group 0.000 abstract 7
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 6
- 125000005842 heteroatom Chemical group 0.000 abstract 6
- 125000002619 bicyclic group Chemical group 0.000 abstract 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 4
- 229910052799 carbon Inorganic materials 0.000 abstract 4
- -1 propylene, propenylene Chemical group 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000006598 aminocarbonylamino group Chemical group 0.000 abstract 2
- 125000001589 carboacyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 abstract 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 abstract 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 abstract 1
- 239000005977 Ethylene Substances 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000005118 N-alkylcarbamoyl group Chemical group 0.000 abstract 1
- 125000005236 alkanoylamino group Chemical group 0.000 abstract 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 abstract 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 1
- 125000005422 alkyl sulfonamido group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 abstract 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 abstract 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 125000003396 thiol group Chemical class [H]S* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/20—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 hydrogenated in the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/54—Radicals substituted by oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un compuesto de fórmula 1: <EMI FILE="98035644_1" ID="1" IMF=JPEG >un profármaco del mismo o las sales farmacéuticamente aceptables de dichos compuestos y profármacos en la que A es hidrógeno o hidroxi; B es propileno, propenileno o propinileno; Q es propileno, -CH2 OCH2 -, tiazolilo, piridilo, fenilo o tienilo; Z es carboxilo, alcoxicarbonilo (C1-C6 ), tetrazolilo, 1, 2, 4-oxadiazolilo o 5-oxo-1, 2, 4-oxadiazolilo; K es etileno o etenileno; L es un enlace o etenileno; L es un enlace o -CO-; M es -Ar, -Ar1-V-Ar2 , -Ar1 -S-Ar2 o -Ar1-0-Ar2 , siendo Ar y Ar1 o (1) cada uno de ellos independientemente un anillo de cinco a ocho elementos totalmente insaturado y que opcionalmente tiene de uno a cuatro heteroátomo seleccionados indepedendientemente entre oxígeno, azufre y nitrógeno, o un anillo bicíclico constituido por dos anillos de cinco nados independientemente entre oxígeno, azufre y nitrógeno, o un anillo bicíclico constituido por dos anillos de cinco y/o seis elementos condensados, parcialmente saturados, totalmente saturados o totalmente insaturados, considerados independientemente, que opcionalmente tienen de uno a cuatro heteroátomos seleccionados independientemente entre nitrógeno, azufre y oxígeno, o un anillo tricíclico constituido por tres anillos de cinco y/o seis elementos condensados, parcialmente saturados, totalmente saturados o totalmente insaturados, considerados independientemente, que opcionalmente tiene uno a cuatro heteroátomos seleccionados independientemente entre nitrógeno, azufre y oxígeno, teniendo opcionalmente cualquiera de dichos anillos parcialmente saturados o totalmente saturados uno o más grupos oxo sustituidos sobre carbono, o (2) cada uno de ellos independientemente un anillo de cinco a ocho elementos totalmente saturado; Ar2 es un anillo de cinco a ocho elementos parcialmente saturado, totalmente saturado o totalmente insaturado y que opcionalmente tiene de uno a cuatro heteroáotomos seleccionados independientemente entre oxígeno, azufre y nitrógeno, o un anillo bicíclico constituido por dos anillos de cinco y/o seis elementos condensados, parcialmente saturados, totalmente saturados o totalmente insaturados, considerados independientemente, que opcionalmente tienen de uno a cuatro heteroátomos seleccionados independientemente entre nitrógeno, azufre y oxígeno, o un anillo tricíclico constituido por tres anillos de cinco y/o seis elementos condensados, parcialmente saturados, totalmente saturados o totalmente insaturados, considerados independientemente, que opcionalmente tiene de uno a cuatro heteroátomos seleccionados - 2 -independientemente entre nitrógeno, azufre y oxígeno, teniendo opcionalmente cualquiera de dichos anillos parcialmente saturados o totalmente saturados uno o más grupos oxo sustituidos sobre carbono; dichos restos Ar y Ar1 , en el caso de un anillo de cinco a ocho elementos totalmente insaturado, un anillo bicíclico o un anillo tricíclico, y dichos restos Ar2 están independientemente opcionalmente sustituidos en el carbono, en un anillo si el resto es monocíclico, en uno o en ambos anillos si el resto es bicíclico, o en uno, dos o tres anillos si el resto es tricíclico, con hasta tres sustituyentes seleccionados entre R1 , R2 y R3 , siendo R1, R2 y R3 independientemente.hidroxi, nitro, halógeno, alcoxi (C1 -C7 ), alcoxi (C1-C4) alquilo (C1-C4 ), alcoxicarbonilo (C1-C4 ), alquilo (C1 -C7 ), alquenilo (C2-C7), alquinilo (C2-C7 ), cicloalquilo (C3-C7 ), cicloalquilo (C3-C7) alquilo (C1-C4), cicloalquilo (C3-C7)alcanoílo (C1-C4 ), formilo, alcanoílo (C1-C8 ), alcanoílo (C1-C6) alquilo (C1-C6), aminocarbonilamino o aminocarbonilamino mono N-, di-N,N-, di-N,N´ o tri-N, N, N´-alquilo (C1-C4 )sustituido, alcanoilamino (C1-C4), alcoxicarbonilamino (C1-C4), sulfonamido, hidroxisulfonilo, alquilsulfonamido (C1-C4 ), amino, mono-N-o di-N,N-alquilamino (C1 -C4), carbamoílo, mono-N- o di-N,N-alquilcarbamoílo (C1-C4), ciano, tiol, alquiltio (C1-C6 ), alquilsulfinilo (C1 -C6 ), alquilsulfonilo (C1 -C4) o mono-N- o di-N,N-alquilaminosulfinilo (C1 -C4 ); R1, R2 y R3 , cuando contienen un resto alquilo, alquenilo, alquileno o alquenileno, son opcionalmente de cadena lineal o ramificada y están opcionalmente mono, di-o tri sustituidos sobre carbono independientemente con halógeno o hidroxi ; y V es un enlace, -CO- o alquileno (C1 -C3 )opcionalmente mono o disustituido independientemente con hidroxi o fluoro, con la condición de que (1 ) cuando L es -CO-, A es hidroxi y (2) cuando L es un enlace y M es fenilo, dicho fenilo está sustituido con uno a tres sustituyentes seleccionados entre R1 , R2 y R3 .
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5057597P | 1997-06-23 | 1997-06-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5080735A1 true CO5080735A1 (es) | 2001-09-25 |
Family
ID=21966050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO98035644A CO5080735A1 (es) | 1997-06-23 | 1998-06-23 | Agonistas de prostaglandinas |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6531485B2 (es) |
| AP (1) | AP9801269A0 (es) |
| AR (1) | AR013118A1 (es) |
| AU (1) | AU7349298A (es) |
| CO (1) | CO5080735A1 (es) |
| GT (1) | GT199800083A (es) |
| HR (1) | HRP980356A2 (es) |
| MA (1) | MA26514A1 (es) |
| PA (1) | PA8452701A1 (es) |
| TN (1) | TNSN98104A1 (es) |
| WO (1) | WO1998058911A2 (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU766163B2 (en) | 1999-03-05 | 2003-10-09 | Duke University | C16 unsaturated fp-selective prostaglandins analogs |
| PT1132086E (pt) | 2000-01-31 | 2006-09-29 | Pfizer Prod Inc | Utilizacao de agonistas selectivos para o receptor da prostaglandina (pge2) 4 (ep4) para o tratamento de falha renal aguda e cronica |
| US20010056060A1 (en) * | 2000-02-07 | 2001-12-27 | Cameron Kimberly O. | Treatment of osteoporsis with EP2/EP4 receptor selective agonists |
| US20020172693A1 (en) | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
| US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| AU2003232845A1 (en) * | 2002-05-29 | 2003-12-12 | Dsm Ip Assets B.V. | Method for the purification of microbial protease |
| JP2006021998A (ja) * | 2002-07-18 | 2006-01-26 | Ono Pharmaceut Co Ltd | Ｅｐ２アゴニストを有効成分とする月経困難症治療剤 |
| DK1563846T3 (da) | 2002-10-10 | 2012-12-17 | Ono Pharmaceutical Co | Endogene reparationsfaktorproduktionsfremmere |
| JP4666257B2 (ja) | 2003-07-25 | 2011-04-06 | 小野薬品工業株式会社 | 軟骨関連疾患治療剤 |
| EP1806148A4 (en) | 2004-10-22 | 2009-12-02 | Ono Pharmaceutical Co | THERAPEUTIC PREPARATION FOR INHALATION |
| US7091231B2 (en) * | 2004-12-10 | 2006-08-15 | Allergan, Inc. | 12-Aryl prostaglandin analogs |
| DK1846354T3 (da) | 2005-01-14 | 2010-08-16 | Allergan Inc | Substituterede cyclopentaner eller cyclopentanoner til behandling af okular hypertensive tilstande |
| BRPI0611079A2 (pt) | 2005-06-03 | 2010-08-03 | Ono Pharmaceutical Co | agentes para a regeneração e/ou proteção de nervos |
| GB0518494D0 (en) * | 2005-09-09 | 2005-10-19 | Argenta Discovery Ltd | Thiazole compounds |
| US7323591B2 (en) | 2006-01-10 | 2008-01-29 | Allergan, Inc. | Substituted cyclopentanes or cyclopentanones as therapeutic agents |
| WO2007149829A2 (en) * | 2006-06-20 | 2007-12-27 | Allergan, Inc. | Therapeutic compounds |
| US7605178B2 (en) * | 2006-07-10 | 2009-10-20 | Allergan, Inc. | Therapeutic compounds |
| WO2008008718A2 (en) * | 2006-07-11 | 2008-01-17 | Allergan, Inc. | Cyclopentane derivatives as antiglaucoma agents |
| NZ582705A (en) | 2007-07-03 | 2012-06-29 | Allergan Inc | Therapeutic substituted cyclopentanes for reducing intraocular pressure |
| US7737140B2 (en) * | 2008-04-24 | 2010-06-15 | Allergan, Inc. | Therapeutic compounds |
| US8569349B2 (en) * | 2008-05-09 | 2013-10-29 | Allergan, Inc. | Therapeutic compounds |
| AU2009246573B2 (en) | 2008-05-15 | 2014-04-24 | Allergan, Inc. | Therapeutic substituted cyclopentanes |
| US20150272874A1 (en) | 2012-10-29 | 2015-10-01 | Cardio Incorporated | Pulmonary disease-specific therapeutic agent |
| JP6449166B2 (ja) | 2013-10-15 | 2019-01-09 | 小野薬品工業株式会社 | 薬剤溶出性ステントグラフト |
| US11795145B2 (en) | 2020-04-21 | 2023-10-24 | Kumiai Chemical Industry Co., Ltd. | Methane-production inhibitor composition and method for inhibiting methane production |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3888905A (en) * | 1969-02-17 | 1975-06-10 | Searle & Co | Prostaglandin intermediates and optically active isomers thereof |
| US3980700A (en) | 1971-10-07 | 1976-09-14 | G. D. Searle & Co. | Prostaglandin intermediates and optically active isomers thereof |
| DE2434133A1 (de) * | 1974-07-12 | 1976-01-22 | Schering Ag | Neue prostansaeurederivate und verfahren zu ihrer herstellung |
| GB1521688A (en) * | 1974-11-01 | 1978-08-16 | May & Baker Ltd | Cyclopentane derivatives |
| US3932389A (en) | 1974-12-11 | 1976-01-13 | Pfizer Inc. | 2-Descarboxy-2-(tetrazol-5-yl)-11-desoxy-15-substituted-.omega.-pentanorprostaglandins |
| US4197407A (en) | 1977-03-30 | 1980-04-08 | American Cyanamid Company | Prostenoic acids and esters |
| US4097601A (en) * | 1977-08-26 | 1978-06-27 | Pfizer Inc. | Bone deposition by 2-descarboxy-2-(tetrazol-5-yl)-11-dexosy-16-aryl prostaglandins |
| HN1996000101A (es) | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
-
1998
- 1998-06-04 WO PCT/IB1998/000866 patent/WO1998058911A2/en active Application Filing
- 1998-06-04 US US09/446,099 patent/US6531485B2/en not_active Expired - Fee Related
- 1998-06-04 AU AU73492/98A patent/AU7349298A/en not_active Abandoned
- 1998-06-08 PA PA19988452701A patent/PA8452701A1/es unknown
- 1998-06-18 GT GT199800083A patent/GT199800083A/es unknown
- 1998-06-18 AP APAP/P/1998/001269A patent/AP9801269A0/en unknown
- 1998-06-22 AR ARP980102993A patent/AR013118A1/es not_active Application Discontinuation
- 1998-06-22 MA MA25129A patent/MA26514A1/fr unknown
- 1998-06-22 TN TNTNSN98104A patent/TNSN98104A1/fr unknown
- 1998-06-23 CO CO98035644A patent/CO5080735A1/es unknown
- 1998-06-23 HR HR60/050,575A patent/HRP980356A2/hr not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MA26514A1 (fr) | 2004-12-20 |
| TNSN98104A1 (fr) | 2005-03-15 |
| AU7349298A (en) | 1999-01-04 |
| WO1998058911A3 (en) | 1999-03-18 |
| WO1998058911A2 (en) | 1998-12-30 |
| GT199800083A (es) | 1999-12-10 |
| US20030008895A1 (en) | 2003-01-09 |
| US6531485B2 (en) | 2003-03-11 |
| AR013118A1 (es) | 2000-12-13 |
| HRP980356A2 (en) | 1999-02-28 |
| AP9801269A0 (en) | 1999-12-18 |
| PA8452701A1 (es) | 2000-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5080735A1 (es) | Agonistas de prostaglandinas | |
| CO5370678A1 (es) | 1,2,3,4-tetrahidroquinolinas 2-sustituidas 4-carboxiamino sustituidas | |
| PE20080155A1 (es) | Compuestos heterociclicos como inhibidores de aspartil-proteasa | |
| AR035783A1 (es) | Compuesto, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para modular efectos de los receptores de histamina 3 | |
| BRPI0518642A2 (pt) | anÁlogos de 12-aril prostaglandina | |
| PA8503301A1 (es) | Compuestos para el tratamiento de la isquemia | |
| CO5630023A2 (es) | Fenil quinolinas y su uso como agentes estrogenicos | |
| EA200100105A1 (ru) | ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ ОКСАЗОЛОВ И ТИАЗОЛОВ В КАЧЕСТВЕ АКТИВАТОРОВ hPPAR ГАММА и hPPAR АЛЬФА | |
| AR065937A2 (es) | Compuesto derivado indazol, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para modular la actividad de proteina quinasa | |
| AR040031A1 (es) | Compuestos de pirazol-pirimidina anilina utiles como inhibidores de cinasa y composiciones farmaceuticas que los contienen | |
| ECSP055582A (es) | Derivados de benzotiazol que tienen actividad agonista de beta-2-adrenorreceptor | |
| TR200101893T2 (tr) | Antiviral maddeler olarak 4-okso-1,4 dihidro -3- kuinolinkarboksamitler. | |
| ATE273305T1 (de) | Thrombin-inhibitoren | |
| DE60107449D1 (de) | Substituierte aminopropoxyarylderivate als lxr agonisten | |
| DE69420564T2 (de) | Immunsuppressive und antiallergische verbindungen; z.b. n-(3-oxohexanoyl)-homoserinlacton | |
| EA200200480A1 (ru) | Пероральные композиции противоопухолевых соединений | |
| KR960701661A (ko) | AIDS치료용 약제학적 배합물중의 HIV프로테아제 억제제(HIV protease inhibitors in pharmaceutical combinations for the treament of AIDS) | |
| KR920014810A (ko) | 항균제 | |
| BR9911175A (pt) | Derivados de ftalazina, composições farmacêuticas contendo os mesmos e uso como inibidores de fosfodiesterase 4 | |
| CO4940477A1 (es) | Inhibidores de proteasa | |
| ES2165586T3 (es) | Derivados de isatina como inhibidores de acetilcolinesterasa y analgesicos. | |
| AR035230A1 (es) | Compuestos de bencimidazol, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion farmaceutica, y usos de estos compuestos para la elaboracion de medicamentos | |
| AR037940A1 (es) | Compuestos antivirales de piridoquinoxalina | |
| DE60330758D1 (de) | Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen | |
| PE20020083A1 (es) | DERIVADOS DE DIPIRIDO[[3,2-b:2',3'-e][1,4] DIAZEPIN-6-ONA COMO INHIBIDORES DE LA TRANSCRIPTASA INVERSA |